Effectiveness of seasonal influenza vaccine in Australia, 2015: An epidemiological, antigenic and phylogenetic assessment

Vaccine

Volumn 34, Issue 41, 2016, Pages 4905-4912

  Fielding, James E ^a,b,c   Levy, Avram ^d,e   Chilver, Monique B ^f   Deng, Yi Mo ^g   Regan, Annette K ^e,h   Grant, Kristina A ^a   Stocks, Nigel P ^f   Sullivan, Sheena G ^c,f,g,i  

^a PETER DOHERTY INSTITUTE FOR INFECTION AND IMMUNITY   (Australia)

^b The Australian National University   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d PATHWEST LABORATORY MEDICINE   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f UNIVERSITY OF ADELAIDE   (Australia)

^g WORLD HEALTH ORGANIZATION   (Switzerland)

^h DEPARTMENT OF HEALTH   (Australia)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Influenza; Influenza like illness; Surveillance; Vaccine effectiveness; Vaccines and immunisation

Indexed keywords

INFLUENZA VACCINE; INACTIVATED VACCINE; VIRUS ANTIGEN;

ADULT; AGED; ANIMAL CELL; ARTICLE; AUSTRALIA; CLADISTICS; CONTROLLED STUDY; DRUG ANTIGENICITY; DRUG EFFICACY; FEMALE; FLU LIKE SYNDROME; HUMAN; INFLUENZA A; INFLUENZA A (H3N2); INFLUENZA A VIRUS (H3N2); INFLUENZA B; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; SEASONAL INFLUENZA; SENTINEL SURVEILLANCE; STUDY DESIGN; YOUNG ADULT; ADOLESCENT; CHILD; IMMUNOLOGY; INFANT; INFLUENZA; INFLUENZA B VIRUS; NEWBORN; PRESCHOOL CHILD;

ADOLESCENT; ADULT; AGED; ANTIGENS, VIRAL; AUSTRALIA; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; SENTINEL SURVEILLANCE; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84990063429     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.08.067     Document Type: Article

References (42)

1. [1] Australian Government Department of Health. National notifiable diseases surveillance system; 2016. < http://www9.health.gov.au/cda/source/cda-index.cfm> [accessed: 21 June 2016].
2. [2] Fielding, J.E., Regan, A.K., Dalton, C.B., Chilver, M.B.-N., Sullivan, S.G., How severe was the 2015 influenza season in Australia?. Med J Aust 204:2 (2016), 60–61.
3. [3] Barr, I., Vijaykrishna, D., Sullivan, S., Differential age susceptibility to influenza B/Victoria lineage viruses in the 2015 Australian influenza season. Euro Surveill, 21(4), 2016 pii=30118.
4. [4] National Health and Medical Research Council, The Australian immunisation handbook. 10th ed., 2013, Australian Government Department of Health and Ageing, Canberra.
5. [5] Australian Institute of Health and Welfare, Adult vaccination survey. 2011, 2009 < http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=10737418286> [accessed: 28 January 2016].
6. [6] Regan, A.K., Tracey, L., Gibbs, R., Post-marketing surveillance of adverse events following immunization with inactivated quadrivalent and trivalent influenza vaccine in health care providers in Western Australia. Vaccine 33:46 (2015), 6149–6151.
7. [7] World Health Organization, Recommended composition of influenza virus vaccines for use in the 2015 southern hemisphere influenza season. Wkly Epidemiol Rec 89:41 (2014), 441–452.
8. [8] Skowronski, D.M., Chambers, C., Sabaiduc, S., De Serres, G., Dickinson, J.A., Winter, A.L., et al. Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's sentinel physician surveillance network, January 2015. Euro Surveill, 20(4), 2015 pii=21022.
9. [9] Jennings, Z., Carter, I., McPhie, K., Kok, J., Dwyer, D.E., Increased prevalence of influenza B/Victoria lineage viruses during early stages of the 2015 influenza season in New South Wales, Australia: implications for vaccination and planning. Euro Surveill, 20(31), 2015 pii=21201.
10. [10] World Health Organization, Recommended composition of influenza virus vaccines for use in the 2015–2016 northern hemisphere influenza season. Wkly Epidemiol Rec 90:11 (2015), 97–108.
11. [11] European Centre for Disease Prevention and Control, Influenza virus characterisation, summary Europe, December 2015. 2016, ECDC, Stockholm.
12. [12] Sullivan, S.G., Carville, K.S., Chilver, M.B., Fielding, J.E., Grant, K.A., Kelly, H.A., et al. Pooled influenza vaccine effectiveness estimates for Australia, 2012–2014. Epidemiol Infect 144:11 (2016), 2317–2328.
13. [13] Sullivan, S.G., Chilver, M.B., Higgins, G., Cheng, A.C., Stocks, N.P., Influenza vaccine effectiveness in Australia: results from the Australian sentinel practices research network. Med J Aust 201:2 (2014), 109–111.
14. [14] Carville, K.S., Grant, K.A., Sullivan, S.G., Fielding, J.E., Lane, C.R., Franklin, L., et al. Understanding influenza vaccine protection in the community: an assessment of the 2013 influenza season in Victoria, Australia. Vaccine 33:2 (2015), 341–345.
15. [15] Levy, A., Sullivan, S.G., Tempone, S.S., Wong, K.L., Regan, A.K., Dowse, G.K., et al. Influenza vaccine effectiveness estimates for Western Australia during a period of vaccine and virus strain stability, 2010 to 2012. Vaccine 32:47 (2014), 6312–6318.
16. [16] Chidlow, G.R., Harnett, G.B., Shellam, G.R., Smith, D.W., An economical tandem multiplex real-time PCR technique for the detection of a comprehensive range of respiratory pathogens. Viruses 1:1 (2009), 42–56.
17. [17] Chidlow, G.R., Harnett, G.B., Speers, D.J., Smith, D.W., Wang, J., Yang, Y., Evaluation of real-time reverse transcriptase PCR assays for detection of pandemic influenza A/H1N1 2009 virus. J Clin Microbiol 49:9 (2011), 3444–3445.
18. [18] Biere, B., Bauer, B., Schweiger, B., Differentiation of influenza B virus lineages Yamagata and Victoria by real-time PCR. J Clin Microbiol 48:4 (2010), 1425–1427.
19. [19] Hobson, D., Curry, R.L., Beare, A.S., Ward-Gardner, A., The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 70:4 (1972), 767–777.
20. [20] Webster, R.G., Laver, W.G., Determination of the number of nonoverlapping antigenic areas on Hong Kong (H3N2) influenza virus hemagglutinin with monoclonal antibodies and the selection of variants with potential epidemiological significance. Virology 104:1 (1980), 139–148.
21. [21] Skehel, J.J., Stevens, D.J., Daniels, R.S., Douglas, A.R., Knossow, M., Wilson, I.A., et al. A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody. Proc Natl Acad Sci U S A 81:6 (1984), 1779–1783.
22. [22] Koel, B.F., Burke, D.F., Bestebroer, T.M., van der Vliet, S., Zondag, G.C., Vervaet, G., et al. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science 342:6161 (2013), 976–979.
23. [23] Foppa, I.M., Haber, M., Ferdinands, J.M., Shay, D.K., The case test-negative design for studies of the effectiveness of influenza vaccine. Vaccine 31:30 (2013), 3104–3109.
24. [24] Newman, L., Stirzaker, S., Knuckey, D., Robinson, K., Hood, J., Knope, K., et al. Australia's notifiable disease status, 2008: annual report of the National Notifiable Diseases Surveillance System. Communicable Diseases Intelligence Quarterly Report 34:3 (2010), 157–224.
25. [25] Levandowski, R.A., Gross, P.A., Weksler, M., Staton, E., Williams, M.S., Bonelli, J., Cross-reactive antibodies induced by a monovalent influenza B virus vaccine. J Clin Microbiol 29:7 (1991), 1530–1532.
26. [26] Skowronski, D.M., Hottes, T.S., De Serres, G., Ward, B.J., Janjua, N.Z., Sabaiduc, S., et al. Influenza B/Victoria antigen induces strong recall of B/Yamagata but lower B/Victoria response in children primed with two doses of B/Yamagata. Pediatr Infect Dis J 30:10 (2011), 833–839.
27. [27] Skowronski, D.M., Hamelin, M.E., Janjua, N.Z., De Serres, G., Gardy, J.L., Rheaume, C., et al. Cross-lineage influenza B and heterologous influenza A antibody responses in vaccinated mice: immunologic interactions and B/Yamagata dominance. PLoS One, 7(6), 2012, e38929.
28. [28] Sočan, M., Prosenc, K., Učakar, V., Berginc, N., A comparison of the demographic and clinical characteristics of laboratory-confirmed influenza B Yamagata and Victoria lineage infection. J Clin Virol 61:1 (2014), 156–160.
29. [29] Tan, Y., Guan, W., Lam, T.T., Pan, S., Wu, S., Zhan, Y., et al. Differing epidemiological dynamics of influenza B virus lineages in Guangzhou, southern China, 2009–2010. J Virol 87:22 (2013), 12447–12456.
30. [30] Xu, C., Chan, K.H., Tsang, T.K., Fang, V.J., Fung, R.O., Ip, D.K., et al. Comparative epidemiology of influenza B Yamagata- and Victoria-lineage viruses in households. Am J Epidemiol 182:8 (2015), 705–713.
31. [31] Fielding, J.E., Grant, K.A., Garcia, K., Kelly, H.A., Effectiveness of seasonal influenza vaccine against pandemic (H1N1) 2009 virus, Australia, 2010. Emerg Infect Dis 17:7 (2011), 1181–1187.
32. [32] Fielding, J.E., Grant, K.A., Tran, T., Kelly, H.A., Moderate influenza vaccine effectiveness in Victoria, Australia, 2011. Euro Surveill, 17(11), 2012 pii=20115.
33. [33] Bissielo, A., Pierse, N., Huang, Q., Thompson, M.G., Kelly, H., Mishin, V.P., et al. Effectiveness of seasonal influenza vaccine in preventing influenza primary care visits and hospitalisation in Auckland, New Zealand in 2015: interim estimates. Euro Surveill, 21(1), 2016 pii=30101.
34. [34] Pebody, R., Warburton, F., Andrews, N., Ellis, J., von Wissmann, B., Robertson, C., et al. Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 end of season results. Euro Surveill, 20(36), 2015 pii=30013.
35. [35] Appiah, G.D., Blanton, L., D'Mello, T., Kniss, K., Smith, S., Mustaquim, D., et al. Influenza activity - United States, 2014–15 season and composition of the 2015–16 influenza vaccine. MMWR Morb Mortal Wkly Rep 64:21 (2015), 583–590.
36. [36] Sullivan, S.G., Feng, S., Cowling, B.J., Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review. Expert Rev Vaccines 13:12 (2014), 1571–1591.
37. [37] Jackson, M.L., Nelson, J.C., The test-negative design for estimating influenza vaccine effectiveness. Vaccine 31:17 (2013), 2165–2168.
38. [38] Orenstein, E.W., De Serres, G., Haber, M.J., Shay, D.K., Bridges, C.B., Gargiullo, P., et al. Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. Int J Epidemiol 36:3 (2007), 623–631.
39. [39] Sullivan, S.G., Tchetgen Tchetgen, E., Cowling, B.J., Theoretical basis of the test-negative design for assessment of influenza vaccine effectiveness. Am J Epidemiol, 2016 in press.
40. [40] Greenland, S., Mansournia, M.A., Altman, D.G., Sparse data bias: a problem hiding in plain sight. BMJ, 352, 2016, i1981.
41. [41] Gaglani, M., Pruszynski, J., Murthy, K., Clipper, L., Robertson, A., Reis, M., et al. Influenza vaccine effectiveness against 2009 pandemic influenza A(H1N1) virus differed by vaccine type during 2013–2014 in the United States. J Infect Dis 213:10 (2016), 1546–1556.
42. [42] Australian Government Department of Health. New flu protections following high season; 2015. < https://www.health.gov.au/internet/ministers/publishing.nsf/Content/health-mediarel-yr2015-ley133.htm> [accessed: 21 January 2016].